After a transformative 2025 driven by positive data across its chronic cough programs, Trevi Therapeutics Inc. (TRVI) is gaining momentum and is now set to begin its first pivotal trial in IPF-related chronic cough this quarter.
Chronic cough is often the first symptom associated with idiopathic pulmonary fibrosis (IPF), a rare and progressive lung disease. Around 150,000 people in the U.S. have IPF. About 60-70% of those with IPF experience uncontrolled coughing, which can be severe, reaching up to 1,500 coughs per day. Currently, there are no approved treatments for chronic cough in IPF patients.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.